First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Cancer Research

Topics

Medicine

Internal Medicine

Molecular Biology

Genetics

Maculopapular Rash

Show all topics

DOI

10.1158/1078-0432.ccr-14-0947